Business Context and Reporting Period
The provided filing is a Form 10-K for DanDrit Biotech USA, Inc., not Lunai Bioworks Inc. It covers the fiscal year ended June 30, 2016. The filing states that the company changed its fiscal year-end from December 31 to June 30 in June 2015; the comparable prior period is therefore the six months ended June 30, 2015. The request metadata references “2015 Q4,” but the source document is an annual fiscal 2016 report.
DanDrit is a clinical-stage biotechnology company developing MelCancerVac (MCV), an investigational dendritic-cell vaccine focused primarily on advanced colorectal cancer. MCV has completed early-stage trials in Denmark and Singapore and has been supplied under a compassionate-use program in Singapore. Neither the FDA nor an equivalent agency had reviewed or approved MCV for commercial marketing.
Financial Performance and Position
| Metric | Year ended June 30, 2016 | Comparable period |
|---|---|---|
| Net sales | $42,769 | $0, six months ended June 30, 2015 |
| Gross profit (loss) | $37,494 | $(65,932) |
| Operating expenses | $2,158,424 | $2,668,633 |
| Loss from operations | $(2,120,930) | $(2,734,565) |
| Net loss | $(1,735,239) | $(2,673,448) |
| Basic and diluted loss per share | $(0.18) | $(0.28) |
| Cash and cash equivalents | $23,368 | $421,145 |
| Working capital/(deficit) | $(775,750) | $910,522 |
| Accumulated deficit | $(26,300,694) | $(24,565,455) |
- Revenue consisted of compassionate-use sales to Singapore and remained immaterial relative to operating costs.
- Research and development expense was $804,188, down from $1,625,488, primarily because of delays in initiating the VIVA Phase III trial.
- General and administrative expense was $1,229,865, down 25%, primarily due to lower legal costs and the resignation of the CFO.
- Consulting expense declined to $96,976 from $295,983 in the comparable audited financial statements, largely reflecting lower fundraising-related fees.
- Cash used in operating activities was $1,472,289. The audited cash-flow statement reports $1,052,989 of cash provided by investing activities, principally from the release of cash previously held in escrow; no cash was provided by financing activities during the year.
- Total assets were $870,831 and total liabilities were $1,508,229 at June 30, 2016, resulting in stockholders’ equity of $(637,398).
- Related-party notes payable totaled $102,882, all classified as current. The filing reports no long-term debt and no derivative liabilities at year-end.
- The company had approximately $10.1 million of Danish tax loss carryforwards and $0.9 million of U.S. tax loss carryforwards, but recorded a full valuation allowance against related deferred tax assets.
Material Changes Versus the Prior Comparable Period
- Sales increased from zero to $42,769 due to compassionate-use activity in Singapore, producing a positive gross margin compared with the prior period’s gross loss.
- Net loss improved by approximately $938,000 in the audited six-month comparison, primarily from lower operating expenses and lower currency and interest expense. The filing’s MD&A also presents an unaudited full-year 2015 comparison, under which net loss improved from $4,161,822 to $1,735,239.
- Cash declined sharply from $421,145 to $23,368, while cash held in escrow declined from $1,052,989 to zero. Working capital changed from a $910,522 surplus to a $775,750 deficit.
- Trade accounts payable increased to $1,087,758 from $512,783, and accrued expenses increased to $220,232 from $16,305.
- Accumulated deficit increased by $1,735,239, and stockholders’ equity moved from $1,077,140 to a deficit of $637,398.
- The CFO resigned effective March 10, 2016; the CEO subsequently served as principal financial and accounting officer.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management planned the VIVA randomized adaptive Phase III trial for 174 stage IV colorectal cancer patients with no evidence of disease after surgery and chemotherapy. The proposed endpoints were relapse-free survival at 18 months and overall survival, with an anticipated duration of approximately three years.
- The company intended to seek clinical-trial authorization in Italy, file an FDA IND to support U.S. participation, and explore a Chinese development and commercialization partnership. These plans were prospective and not assurances of trial commencement, regulatory approval, or commercialization.
- Management stated that additional financing is required and that the company did not have sufficient cash to sustain operations for the next 12 months. The filing raises substantial doubt about the company’s ability to continue as a going concern.
- Management proposed raising capital through debt, equity, private placements, collaborations, and licensing arrangements. The filing disclosed an attempted $15 million or greater private placement linked to a proposed OncoSynergy asset acquisition, but stated that completion was not assured.
- Subsequent to year-end, the company entered into or received commitments for several 1% convertible notes, generally maturing December 31, 2017 and convertible at $2.00 per share. It also entered into a $20,000-per-month financial services agreement with an entity owned by a director and granted three 300,000-share option awards at $2.00 per share.
- The April 2016 OncoSynergy asset purchase agreement contemplated issuing consideration that would result in OncoSynergy holders owning an estimated 33% to 40% of the combined company on a fully diluted basis, subject to closing.
- The company reported material weaknesses in internal control over financial reporting, including insufficient accounting resources and inadequate segregation of duties. Disclosure controls and procedures were deemed ineffective as of June 30, 2016.
- Key risks include failure of MCV to demonstrate efficacy or safety in Phase III trials, inability to obtain FDA or foreign regulatory approval, patient-enrollment and manufacturing delays, dependence on third parties and financing, competition from better-funded biotechnology companies, intellectual-property challenges, product-liability exposure, foreign-currency fluctuations, and limited market liquidity.
- The independent auditor issued an unqualified opinion but highlighted substantial doubt regarding the company’s ability to continue as a going concern.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the filing is for DanDrit Biotech USA, Inc., while the request identifies Lunai Bioworks Inc.
- Confirm the relevant period: the filing is an annual report for the fiscal year ended June 30, 2016, not a 2015 fourth-quarter filing.
- Reconcile the conflicting prior-period comparisons in the MD&A, which presents both six-month 2015 unaudited data and an unaudited full-year 2015 presentation.
- Verify available cash, current liabilities, related-party debt, and the going-concern disclosure before relying on the company’s operating plans.
- Verify whether the VIVA Phase III trial, FDA IND plans, proposed China collaboration, private placement, and OncoSynergy transaction were subsequently completed.
- Assess the effect of subsequent convertible notes and stock options on potential dilution and future financing needs.
- Review remediation of the material weaknesses in internal controls and any later auditor or SEC comments.
- Distinguish historical early-stage trial observations and compassionate-use sales from regulatory approval, randomized efficacy evidence, or recurring commercial revenue.